TY - JOUR T1 - Fecal microbiota transplantation in ulcerative colitis, a retrospective microbiome analysis JF - medRxiv DO - 10.1101/2020.03.25.20043182 SP - 2020.03.25.20043182 AU - Marcel A. de Leeuw AU - Manuel X. Duval Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/12/2020.03.25.20043182.abstract N2 - Background Inflammatory bowel disease (IBD) is a set of conditions characterized by non-infectious chronic inflammation of the gastrointestinal tract. These primarily include Crohn’s disease (CD), ulcerative colitis (UC) and indeterminate colitis. Fecal microbiota transplantation (FMT) has proven to be an effective treatment for some patients with active UC. However, factors contributing to the individual response to FMT therapy remain to be uncovered. There is currently no procedure allowing to predict the patients’ response and to select the most adequate donor(s).Methods The first available UC longitudinal FMT microbiome data sets were reanalyzed, with focus on species level changes in the microbiota, using state-of-the-art and in part proprietary 16S analysis routines.Results We found the microbiomes of UC and CD patients to have paucity of obligate anaerobes, which could be a consequence of oxidative stress. Microbiomes of UC FMT responders and responder donors have higher phylogenetic diversity and a higher proportion of aerobes and facultative anaerobes as compared to non-responders and non-responder donors. We found Proteobacteria to account for the major part of species found in increased relative abundance in responders. Sphingolipid producers were found among these species.Implications Our findings contribute to the establishment of selection criteria for UC FMT donor samples and composition guidelines for future synthetic microbial communities. Instead of replenishing missing obligate anaerobes, our results suggest that oxidative stress resistant Proteobacteria are important for the establishment of an anaerobic environment and a successful UC FMT therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors did not receive funding for the work presented.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and scripts required to reproduce the analysis are available from the following GitHub archive https://github.com/GeneCreek/UC-manuscript https://github.com/GeneCreek/UC-manuscript ER -